Related Experiment Video
Updated: Feb 7, 2026
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation
Murat Lekili1, Talha Muezzinoglu, Nalan Nese
1Department of Urology, School of Medicine, Celal Bayar University, School of Medicine, Uncubozköy Mevkii, Kat 8, Manisa, Turkey. lekili@superonline.com
Abstract:
Targeted therapy in the management of metastatic renal cell cancer has been recently introduced to urology practice. The drugs used for management are used in a very limited number of patients and only for clear cell histology. We present a case where we administered sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, to a patient with metastatic renal cell carcinoma of clear cell histology. We found that our results were different from those of previously reported studies, because sarcomatoid differentiation was evident in a histological examination of this case. There was an excellent response to sorafenib. This case report might provide evidence that antiangiogenic agents may be active in any histological type of renal cell carcinoma. However, there are no available data to demonstrate the duration of response and survival benefit.
Insights
This case study shows an excellent response to sorafenib in metastatic renal cell carcinoma, even with sarcomatoid differentiation. Antiangiogenic agents may benefit broader renal cell carcinoma patient populations.
Area of Science:
- Oncology
- Urology
Background:
- Metastatic renal cell carcinoma (mRCC) management is evolving with targeted therapies.
- Current targeted therapies are restricted to specific patient groups and clear cell histology.
Observation:
- A patient with metastatic renal cell carcinoma (mRCC) and sarcomatoid differentiation received sorafenib.
- Sorafenib is a multikinase inhibitor targeting tumor proliferation and angiogenesis.
Findings:
- The patient exhibited an excellent response to sorafenib therapy.
- Histological examination revealed sarcomatoid differentiation, a factor not typically associated with targeted therapy response.
Implications:
- This case suggests antiangiogenic agents like sorafenib may be effective across various renal cell carcinoma (RCC) histological types.
- Further research is needed to confirm response duration and survival benefits in diverse RCC subtypes.
More Related Videos
Related Concept Videos
01:22iPS Cell Differentiation
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...